Compare AKR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | TARS |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 1996 | 2020 |
| Metric | AKR | TARS |
|---|---|---|
| Price | $21.34 | $59.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $22.25 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 0.22 | N/A |
| Revenue | $410,757,000.00 | ★ $451,360,000.00 |
| Revenue This Year | $3.21 | $56.43 |
| Revenue Next Year | $12.17 | $30.19 |
| P/E Ratio | $96.77 | ★ N/A |
| Revenue Growth | 14.20 | ★ 146.71 |
| 52 Week Low | $18.06 | $38.51 |
| 52 Week High | $22.90 | $85.25 |
| Indicator | AKR | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 43.88 |
| Support Level | $20.82 | $59.16 |
| Resistance Level | $21.62 | $67.14 |
| Average True Range (ATR) | 0.35 | 4.52 |
| MACD | -0.02 | -0.47 |
| Stochastic Oscillator | 41.73 | 20.11 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: REIT Portfolio segment consists of high-quality retail properties located in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds the retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.